SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

Attention centers on ABCL635, AbCelleras antibody candidate for menopausal hot flashes, and its Phase 1/2 data presentation at a menopause conference; traders are looking for added evidence on efficacy, durability and safety after encouraging Phase 2 topline results. Bulls see the data as a potential validation of the companys internal pipeline, while skeptics question whether the presentation adds enough beyond known results and warn that expectations and recent volatility may set up a sell-the-news reaction.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

Renewed, unconfirmed takeover chatter around a possible offer from an unidentified West Coast technology company is dominating discussion, with traders speculating about buyers such as Meta while others caution that no bid has been confirmed. Upcoming earnings and concerns about transaction margins are also in focus, but the takeover speculation is driving much of the debate.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak quarterly results, sharply reduced full-year outlook and suspended dividend are driving attention, alongside managements warning of recession-level appliance demand and its attribution of the downturn partly to the Iran war. Traders are debating whether the selloff reflects severe financial and management problems or an overreaction that could create a contrarian buying opportunity; no article was provided that directly supports the catalyst.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Attention centers on Helus Pharmas expected Q4 2026 Phase 3 topline results for HLP003, its investigational add-on treatment for major depressive disorder. Traders are split between optimism that the readout could validate the program and concerns about trial uncertainty, potential dilution, and volatility around the binary catalyst.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is drawing attention amid a steep, prolonged selloff, with traders citing weakness across Chinese EV stocks, concerns about demand, profitability and analyst downgrades. Bulls counter that delivery growth, European expansion and AI-chip and robotics initiatives could support the business, while frustrated holders question whether those developments can improve shareholder returns.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWMs choppy trading is drawing attention amid rotation between small caps and large-cap tech, with traders debating whether small caps relative resilience signals a broader recovery or a temporary bounce. Speculation about a U.S.Iran deal and swings in oil prices have added volatility, but the reported diplomatic progress is disputed and traders remain wary of weak breadth and technical resistance.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas Phase 3 melanoma-vaccine results with Keytruda showed a 42% reduction in recurrence or death risk, but shares sold off as traders judged the outcome against high expectations after a major run-up. The community is split between viewing the data as strong validation of the cancer-vaccine platform and questioning whether the benefit, individualized manufacturing, and commercialization prospects justify the valuation.

Caterpillar, Inc. engages in the business of manufacturing construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives. It operates through the following segments: Construction Industries, Resource Industries, Power and Energy, and All Other. The Construction Industries segment is involved in supporting customers using machinery in infrastructure and building construction applications. The Resource Industries segment offers machinery in mining, heavy construction, quarry, and aggregates. The Power and Energy segment focuses on reciprocating engines, turbines, diesel-electric locomotives, and related services across industries serving oil and gas, power generation, industrial, and transportation applications including marine- and rail-related businesses. The All Other segment includes activities such as the business strategy, product management and development, manufacturing, and sourcing of wear and maintenance components products, parts distribution, integrated logistics solutions, distribution services responsible for dealer development, and administration. The company was founded on April 15, 1925, and is headquartered in Irving, TX.

Caterpillar Inc.

Caterpillars sharp pullback and upcoming earnings report are driving debate, with traders questioning whether strong backlog and data-center power demand can justify elevated expectations or whether the selloff reflects concerns about slowing AI infrastructure spending. Some see the stock as oversold and are buying the dip, while others expect further weakness if guidance disappoints.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Novartis/Aviditys Phase 3 failure in myotonic dystrophy type 1 has prompted a selloff and focused attention on whether the result also challenges Sareptas SRP-1003 program. Traders debate whether Sareptas different delivery approach and forthcoming DM1 and FSHD readouts can distinguish its pipeline, or whether the rival trial raises the bar for proving functional benefit.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica is drawing attention ahead of its earnings report and investor day, with traders also watching hyperscaler results for clues about AI infrastructure demand. The community is divided between expecting strong results and continued growth, and worrying that the broader AI-stock selloff and valuation reset could outweigh solid company fundamentals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Billionaire Mark Cuban And Humana Tease A New Pharmacy Deal Aimed At Cutting Out Middlemen: Report

Equity

The announcement was made by Cuban and Humana CEO at the Forbes health care conference, Bloomberg reported.


Moderna Brings Back Drug Product Manufacturing To Home Ground

The company said it has commenced construction at the Massachusetts facility, which is slated for completion in the first half of 2027.

Ford Sales In US Rise 1.6% In October On Continued Truck Demand

The growth was primarily driven by a 3.4% growth in sales of the company’s internal combustion engine vehicles. 

Ford Faces Up To $1 Billion Hit After New York Aluminum Plant Fire, Analysts Reportedly Say

According to a Reuters report, Ford refused to comment on Evercore’s estimates.

Pimco Equity Series - Pimco Rafi ESG U.S. ETF

Neutral Sentiment

<ul class="summary-bullets"><li>Cuban reportedly said that he was talking to Humana about “putting together direct-to-employer programs”.</li><li>Cuban sells mail-order medications directly to customers through Cost Plus Drugs company by removing middlemen such as pharmacy benefit managers.</li><li>Humana, meanwhile, is expanding its pharmacy business.</li></ul><p>Health insurance company Humana (HUM) is reportedly working with billionaire Mark Cuban on a potential pharmacy partnership.</p><p>The announcement was made by Cuban and Humana CEO at the Forbes health care conference, Bloomberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-12-04/humana-working-with-mark-cuban-on-potential-pharmacy-partnership?srnd=homepage-asia">reported</a>. While the announcement was light on details, the move would step up pressure on larger pharmacy middlemen, the report noted.</p><h2 class="st-heading-2">Cuban, Humana Talk About Partnership</h2><p>Cuban reportedly said that he was talking to Humana about “putting together direct-to-employer programs”. Humana CEO Jim Rechtin also highlighted that he is looking to simplify the process of getting drugs from manufacturers to patients, Bloomberg reported.</p><p>Cuban sells mail-order medications directly to customers through Cost Plus Drugs company by removing middlemen such as pharmacy benefit managers. The billionaire is critical of pharmacy benefit managers. Last month, the billionaire blamed PBMs for hiking the prices of GLP-1 drugs used for weight loss and as a treatment for diabetes.</p><p>Pharmacy benefit managers (PBMs) are third-party administrators that act as intermediaries between health insurance plans, pharmacies, and drug manufacturers to manage prescription drug benefits.</p><h2 class="st-heading-2">Humana’s Pharmacy Business</h2><p>Humana, meanwhile, is expanding its pharmacy business. It offers pharmacy under its CenterWell business division which also includes senior-focused primary care and home health services. In November, the company said that it witnessed continued strong CenterWell pharmacy growth with increased specialty volumes and strong direct to consumer growth, both exceeding previous expectations in 3Q25.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>HUM shares traded closed down about 2% on Thursday. On Stocktwits, retail sentiment around HUM stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.</p><p><a href="https://stocktwits.com/symbol/HUM">HUM stock</a> is down marginally this year and by about 12% over the past 12 months.</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pepsico-close-to-striking-settlement-with-activist-giant-elliott-after-4-billion-push-for-change/cLIi4iXREj1">PepsiCo Is Close To Striking A Settlement With Activist Giant Elliott After Its $4B Push For Change</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

The MyHumana app page is displayed on a smartphone in the Apple App Store in front of the Humana Inc logo on October 30, 2024 in Chongqing, China. (Photo by Cheng Xin/Getty Images)

The announcement was made by Cuban and Humana CEO at the Forbes health care conference, Bloomberg reported.

Amplify AI Powered Equity ETF

Humana Inc

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$50.26
Prev Close	$50.74
Open	$50.10
Dividend Yield	N/A
50-Day Moving Average	$49.96
Beta	N/A
Avg. Volume	18,854.83
PE Ratio	N/A

52-Week High	$50.84
52-Week Low	$39.79
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

RAFE Fundamentals